A no-deal Brexit would break the medicines supply chain

70% of our medicines come from, or through, the UK, but after it departs the EU, it will no longer be part of our regulatory jurisdiction. We must protect patients, writes Bernard Mallee.

For the past two years, pharmaceutical companies, which discover and make branded, prescription medicines, have been working on Brexit planning, investing huge time and money on potential changes in how medical products will get to patients after the UK leaves the European Union.